16
Treatment
Table 14. Smoking Cessation
COR LOE
Recommendations
I A Patients with PAD who smoke cigarettes or use other forms of
tobacco should be advised at every visit to quit.
I A Patients with PAD who smoke cigarettes should be assisted in
developing a plan for quitting that includes pharmacotherapy
(i.e., varenicline, bupropion, and/or nicotine replacement
therapy) and/or referral to a smoking cessation program.
I B-NR Patients with PAD should avoid exposure to environmental
tobacco smoke at work, at home, and in public places.
Table 15. Glycemic Control
COR LOE
Recommendations
I C-EO Management of diabetes mellitus in the patient with PAD should
be coordinated between members of the healthcare team.
IIa B-NR Glycemic control can be beneficial for patients with CLI to
reduce limb-related outcomes.
Table 16. Oral Anticoagulation
COR LOE
Recommendations
IIb B-R e usefulness of anticoagulation to improve patency aer lower
extremity autogenous vein or prosthetic bypass is uncertain.
III:
Harm
A Anticoagulation should NOT be used to reduce the risk of
cardiovascular ischemic events in patients with PAD.
Table 17. Recommendation for Cilostazol
COR LOE
Recommendation
I A Cilostazol is an effective therapy to improve symptoms and
increase walking distance in patients with claudication.
Table 18. Recommendation for Pentoxifylline
COR LOE
Recommendation
III: No
Benefit
B-R Pentoxifylline is not effective for treatment of claudication.
